Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
about
5-HT3 receptorsThe 5-HT3 receptor as a therapeutic targetThe role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatmentsNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsMechanisms of acupuncture-electroacupuncture on persistent painSome of the challenges in drug development for irritable bowel syndromeFunctional GI disorders: from animal models to drug development.Stress and visceral pain: from animal models to clinical therapiesIncidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.Pharmacology and clinical experience with alosetron.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?Review article: clinical pharmacology of alosetron.Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicinePathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain.Serotonin: a mediator of the brain-gut connection.Irritable bowel syndrome: an update on therapeutic modalities.Emerging treatments for irritable bowel syndrome.Guidelines on the irritable bowel syndrome: mechanisms and practical management.Alosetron and irritable bowel syndrome.Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls.Serotonergic modulation of visceral sensation: upper gastrointestinal tract.Serotonergic modulation of visceral sensation: lower gut.Serotonergic modulating drugs for functional gastrointestinal diseases.Ligand-gated ion channels in the enteric nervous system.Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.Role of serotonin in the pathophysiology of the irritable bowel syndrome.The role of experimental models in developing new treatments for irritable bowel syndrome.Novel therapies in the treatment of irritable bowel syndrome.Evaluation of drug treatment in irritable bowel syndrome.The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndromePharmacology of serotonin: what a clinician should know.Diagnosis and therapy of irritable bowel syndrome.Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trialReview article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence.
P2860
Q24648000-F2BA5FCC-DEB7-4F52-B1B0-C994EAEA3CE8Q24681066-8C72C7AE-5333-42D2-BB15-7CC0D789D3C5Q26739291-C88FA29F-BA13-4E4B-990D-9C2554109514Q26748617-E17892F3-D20B-43A6-8091-8478954F24F1Q26866252-CABFCC1B-932B-42CC-956C-F90F847415F8Q28362604-FE91083F-8575-499A-86F2-E56D20FBED10Q30433078-07098E2C-FE6B-4539-97CA-5C944246CD4FQ30459512-31B48830-0767-4F90-AE53-C69DB6A09003Q31036400-B165C253-15FB-4F2B-A02B-C28030785C9EQ31521286-4B94E06E-5EE8-4BB7-B0F8-EFE0370E3FFAQ33451900-0C2E1464-BEEE-4E40-8D9A-0CFE15DED634Q33466527-9531505A-A6EF-4E3E-A739-2F6748EAF47BQ33656496-2CE78B37-90BB-4EE5-9B1F-D559795BC792Q33701301-3427F5D4-5CFE-434D-86D1-6FF4585B55B4Q33701309-2400EB62-EE43-4B54-9EF5-A6FD73CA9D3FQ33735229-321835B3-2259-4867-B4EC-653D71FD5BB0Q33912707-6384CDC9-3B06-41BA-93C9-78448572C0BFQ34070408-DF996264-E733-4096-8BE2-FD5C73E7A233Q34481528-7A164F3E-2C1D-4994-B148-09E15D58BEBDQ34482014-19A5DC35-1C30-4C68-8A99-8219753C7FDDQ34626602-D91D4177-6F00-4E1A-8B5E-7235BE70A0E3Q34649076-6A6881A0-1E94-4118-9C49-3F382BE2ECFCQ34699804-51FB2B94-1C45-4B5B-93FD-43A2D9AD5852Q34699852-FED81013-4114-42DD-9A74-A809ED40D16DQ34699859-133D9122-2AD0-43BD-8D35-AA299EF47CBEQ34722737-40B113C9-14A7-471F-AA44-F56E782BBF91Q35015772-5FFB449C-5135-419A-85CA-8ED710A0E914Q35021543-A18B81F4-BE86-4847-919C-47D916BFC8DCQ35047066-81A27FCA-E9BB-44FA-B0D3-41ED576BD8A2Q35071310-EA511C1B-C824-422D-9760-417A0AEAE4B4Q35094684-0B7C7D31-F6F9-43DD-AF4C-675929F999ACQ35216829-AF0BF417-7274-4F45-85D3-8B13664050C1Q35359830-D9A72D4A-B191-4E72-BEB4-9DCFBB4005A5Q35362266-A3BD58DC-1B85-4A7C-B0E5-F7E5736EFC87Q35596862-07502821-01A2-4119-94F9-A0191C7B5A57Q35873847-C2B21C9A-9607-483E-AAAB-E6DC06F48FB5Q35985391-04E2D779-5E0B-4766-B17A-2E27DA9358C2Q36023377-9DE0D24E-7582-4F27-9B31-EE3248B09B60Q36055161-CF44E793-4597-4CCF-A1D4-233D930098A3Q36072575-9F9027FA-F538-4AC9-95EF-D9883E650008
P2860
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Effect of alosetron on respons ...... with irritable bowel syndrome.
@en
Effect of alosetron on respons ...... with irritable bowel syndrome.
@nl
type
label
Effect of alosetron on respons ...... with irritable bowel syndrome.
@en
Effect of alosetron on respons ...... with irritable bowel syndrome.
@nl
prefLabel
Effect of alosetron on respons ...... with irritable bowel syndrome.
@en
Effect of alosetron on respons ...... with irritable bowel syndrome.
@nl
P2093
P2860
P1476
Effect of alosetron on respons ...... with irritable bowel syndrome.
@en
P2093
Campos-Oriola R
Frexinos J
P2860
P304
P356
10.1046/J.1365-2036.1998.00375.X
P407
P577
1998-09-01T00:00:00Z